AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s
Executive Summary
Data showing superiority on endoscopic remission and non-inferiority on clinical remission could position AbbVie’s IL-23 inhibitor to move ahead of Stelara in treatment paradigm.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab
Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.
Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business
US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira.